NO921364L - Hybridpolypeptid - Google Patents

Hybridpolypeptid

Info

Publication number
NO921364L
NO921364L NO92921364A NO921364A NO921364L NO 921364 L NO921364 L NO 921364L NO 92921364 A NO92921364 A NO 92921364A NO 921364 A NO921364 A NO 921364A NO 921364 L NO921364 L NO 921364L
Authority
NO
Norway
Prior art keywords
polypeptide
hybrid
avidin
interest
high yield
Prior art date
Application number
NO92921364A
Other languages
English (en)
Other versions
NO921364D0 (no
Inventor
Dean Ervin Cress
Ferdinand Carl Haase
Original Assignee
Rohm & Haas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rohm & Haas filed Critical Rohm & Haas
Publication of NO921364D0 publication Critical patent/NO921364D0/no
Publication of NO921364L publication Critical patent/NO921364L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/675—Beta-endorphins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1003—Transferases (2.) transferring one-carbon groups (2.1)
    • C12N9/1018—Carboxy- and carbamoyl transferases (2.1.3)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Det omtales et hybridpolypeptid som omfatter et avidin- bindingspolypeptid som inneholder et biotinbindingsområde fusjonert med et interesserede polypeptid hvor avidinbindings- "polypeptidet befinner seg "oppstrøms" for det interesserende polypeptid. Hybridpolypeptidet fremstilles ved rekombinant DNA-teknikk. Hybridpolypeptidet kan også inneholde et spaltingssete for spalting av det interesserende polypeptid fra avidinbidingspolypeptidet ved anvendelse av egnet proteo- lytisk eller kjemisk middel. Hybridpolypeptidet uttrykkes i egnete vertceller transformert med DNA-ekspresjonsvektoren som koder for hybridpolypeptidet og kan utvinnes fra råcelle- ekstrakter i høyt utbytte og med høy renhet ved avidinaffini- tetskromatografi. Etter avidinaffinitetsrensingen kan interes- serende polypeptid fraspaltes og derved oppnås i en ren og høvaktiv tilstand.
NO92921364A 1991-04-19 1992-04-08 Hybridpolypeptid NO921364L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/687,819 US6072039A (en) 1991-04-19 1991-04-19 Hybrid polypeptide comparing a biotinylated avidin binding polypeptide fused to a polypeptide of interest

Publications (2)

Publication Number Publication Date
NO921364D0 NO921364D0 (no) 1992-04-08
NO921364L true NO921364L (no) 1992-10-20

Family

ID=24761988

Family Applications (1)

Application Number Title Priority Date Filing Date
NO92921364A NO921364L (no) 1991-04-19 1992-04-08 Hybridpolypeptid

Country Status (13)

Country Link
US (1) US6072039A (no)
EP (1) EP0511747A1 (no)
JP (1) JPH06166698A (no)
KR (1) KR920019820A (no)
AU (1) AU659139B2 (no)
BR (1) BR9201437A (no)
CA (1) CA2064933A1 (no)
FI (1) FI921740L (no)
IE (1) IE921250A1 (no)
IL (1) IL101454A0 (no)
MX (1) MX9201749A (no)
NO (1) NO921364L (no)
NZ (1) NZ242395A (no)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5541087A (en) * 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
WO1996021156A1 (en) * 1995-01-04 1996-07-11 Abbott Laboratories Method for preparing scintillation proximity assay targets
ES2590912T3 (es) 1997-12-08 2016-11-24 Merck Patent Gmbh Proteínas de fusión heterodiméricas útiles para inmunoterapia dirigida y estimulación general del sistema inmunitario
EP0985931A3 (en) * 1998-09-04 2000-03-29 Becton Dickinson and Company Recombinant antigen immunoassay for the diagnosis of syphilis
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
MXPA02001417A (es) 1999-08-09 2002-08-12 Lexigen Pharm Corp Complejos multiples de citosina-anticuerpo.
DE19952956A1 (de) 1999-11-03 2001-05-17 Acgt Progenomics Ag Verfahren zur Verbindung von molekularen Substanzen
CA2391080A1 (en) 1999-11-12 2001-05-25 Merck Patent Gesellschaft Mit Beschraenkter Haftung Erythropoietin forms with improved properties
HUP0204475A2 (en) 2000-02-11 2003-04-28 Merck Patent Gmbh Enhancing the circulating half-life of antibody-based fusion proteins
KR20030064275A (ko) 2000-06-29 2003-07-31 메르크 파텐트 게엠베하 면역싸이토카인 흡수 증강제와의 조합 치료에 의한항체-싸이토카인 융합 단백질 매개 면역 반응 증강
US20020142355A1 (en) * 2000-11-14 2002-10-03 Baylor College Of Medicine Methods for the in vivo biotin labeling of polypeptides
RU2003129528A (ru) 2001-03-07 2005-04-10 Мерк Патент ГмбХ (DE) Способ экспрессии белков, содержащих в качестве компонента гибридный изотип антитела
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
EP1383785B1 (en) 2001-05-03 2011-03-16 Merck Patent GmbH Recombinant tumor specific antibody and use thereof
US7270960B2 (en) 2001-08-29 2007-09-18 Pacific Northwest Research Institute Diagnosis of ovarian carcinomas
DK1454138T3 (da) 2001-12-04 2012-02-13 Merck Patent Gmbh Immunocytokiner med moduleret selektivitet
WO2003050540A2 (en) * 2001-12-05 2003-06-19 Large Scale Biology Corporation Flexible method and apparatus for high throughput production and purification of multiple proteins
GB0202018D0 (en) * 2002-01-29 2002-03-13 Sense Proteomic Ltd Tag and method
US20040067532A1 (en) 2002-08-12 2004-04-08 Genetastix Corporation High throughput generation and affinity maturation of humanized antibody
WO2004055056A1 (en) 2002-12-17 2004-07-01 Merck Patent Gmbh Humanized antibody (h14.18) of the mouse 14.18 antibody binding to gd2 and its fusion with il-2
CA2529623A1 (en) 2003-06-16 2005-02-17 Celltech R & D, Inc. Antibodies specific for sclerostin and methods for increasing bone mineralization
ES2305886T3 (es) 2003-12-30 2008-11-01 Merck Patent Gmbh Proteinas de fusion de il-7 con porciones de anticuerpo, su preparacion y su empleo.
RU2370276C2 (ru) 2003-12-31 2009-10-20 Мерк Патент Гмбх Fc-ЭРИТРОПОЭТИН СЛИТЫЙ БЕЛОК С УЛУЧШЕННОЙ ФАРМАКОКИНЕТИКОЙ
AU2005206277B2 (en) 2004-01-22 2011-06-23 Merck Patent Gmbh Anti-cancer antibodies with reduced complement fixation
US7670595B2 (en) 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
RU2437893C2 (ru) 2004-12-09 2011-12-27 Мерк Патент Гмбх Варианты il-7 со сниженной иммуногенностью
DE102005040347A1 (de) 2005-08-25 2007-03-01 Profos Ag Verfahren und Mittel zur Anreicherung, Entfernung und zum Nachweis von Listerien
PL1966238T3 (pl) 2005-12-30 2012-09-28 Merck Patent Gmbh Warianty interleukiny-12p40 o polepszonej stabilności
ES2365046T3 (es) 2005-12-30 2011-09-21 Merck Patent Gmbh Anticuerpos anti-cd19 con inmunogenicidad reducida.
DK2005185T3 (da) 2006-03-22 2011-01-31 Viral Logic Systems Technology Corp Fremgangsmåde til identifikation af polypeptidtargets
US8377448B2 (en) 2006-05-15 2013-02-19 The Board Of Trustees Of The Leland Standford Junior University CD47 related compositions and methods for treating immunological diseases and disorders
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
EP3124497B1 (en) 2007-09-14 2020-04-15 Adimab, LLC Rationally designed, synthetic antibody libraries and uses therefor
US12529164B2 (en) 2007-09-14 2026-01-20 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
SG175233A1 (en) 2009-04-22 2011-11-28 Merck Patent Gmbh Antibody fusion proteins with modified fcrn binding sites
EP2527431A1 (en) 2011-05-26 2012-11-28 bioMérieux S.A. Novel Listeria bacteriophage tailspike protein and uses thereof
US20150099860A1 (en) * 2013-10-08 2015-04-09 Proteins Easy Corp Methods for separating and purifying endogenous, exogenous and recombinant proteins/peptides from plants and animals using aqueous-free, anhydrous strategies
CN106156530A (zh) * 2016-08-03 2016-11-23 北京好运到信息科技有限公司 基于栈式自编码器的体检数据分析方法及装置

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4839293A (en) * 1986-02-24 1989-06-13 The Trustees Of Columbia University In The City Of New York DNA encoding streptavidin, streptavidin produced therefrom, fused polypeptides which include amino acid sequences present in streptavidin and uses thereof
AU2635088A (en) * 1987-12-04 1989-06-08 Du Pont Merck Pharmaceutical Company, The Immobilized interleukin 2 and interleukin 2 containing a carboxyl-terminal extension
AU3342689A (en) * 1988-03-24 1989-10-16 Igen Incorporated Luminescent chimeric proteins
JPH04507341A (ja) * 1989-05-19 1992-12-24 バイオテクノロジー　リサーチ　アンド　ディヴェロプメント　コーポレーション ｉｎ　ｖｉｖｏ翻訳後修飾部位を有する融合タンパク質及び製造及び精製方法
US5874239A (en) * 1993-07-30 1999-02-23 Affymax Technologies N.V. Biotinylation of proteins

Also Published As

Publication number Publication date
NZ242395A (en) 1993-12-23
FI921740A0 (fi) 1992-04-16
AU659139B2 (en) 1995-05-11
CA2064933A1 (en) 1992-10-20
NO921364D0 (no) 1992-04-08
BR9201437A (pt) 1992-12-01
EP0511747A1 (en) 1992-11-04
JPH06166698A (ja) 1994-06-14
US6072039A (en) 2000-06-06
MX9201749A (es) 1992-10-01
FI921740A7 (fi) 1992-10-20
AU1398792A (en) 1992-10-22
IE921250A1 (en) 1992-10-21
IL101454A0 (en) 1992-12-30
FI921740L (fi) 1992-10-20
KR920019820A (ko) 1992-11-20

Similar Documents

Publication Publication Date Title
NO921364L (no) Hybridpolypeptid
Sundkvist et al. Structure and function of free 40 S ribosome subunits: Characterization of initiation factors
AU3676595A (en) Expression and export technology of proteins as immunofusins
EP0824148A3 (en) Polyester synthase gene and process for producing polyester
AU2812484A (en) Dna vectors and there use in recombinant dna technology
DE69109109D1 (de) Ubiquitinspezifische protease.
ES2183960T3 (es) ,cj2, una cisteimproteasa apoptotica, y composiciones para producirla y metodos de utilizacion.
EP0236978A3 (en) Production of factor xiiia by gene technology
AU583388B2 (en) High performance liquid chromatography mobile phase
KR870004139A (ko) 인체 λ-인터페론의 생물학적 활성 유도체를 제조하는 방법
EA200000202A1 (ru) Рекомбинантная экспрессия c-пептида инсулина
Lai Studies on the structure of rabbit muscle aldolase: Determination of the primary structure of the COOH-terminal BrCN peptide; the complete sequence of the subunit polypeptide chain
ATE79409T1 (de) Herstellungsverfahren fuer humanes atriales natriuretisches polypeptid.
DE60029791D1 (de) Rezeptor eines neurotrophen faktors (gfr-alpha-4)
HUT69979A (en) Method for producing protein c
IE810114L (en) N-benzyloxycarbonyl-l-aspartic acid
KR860008283A (ko) 인체 췌장 엘라스타제의 제조방법
GB2073204A (en) Process for producing an insulin precursor
CA2241367A1 (en) Vector for expression of n-terminally extended proteins in yeast cell
Qureshi et al. The isolation of acyl carrier protein from the pigeon liver fatty acid synthetase complex II
Polayes et al. Efficient protein expression and simple purification using the pPROEX-1 super (TM) system
Müller et al. The biosynthesis of a precursor of cartilage collagen by embryonic chicken sterna in the presence of α, α′-dipyridyl
DE59814240D1 (de) Hyaluronidase enthaltendes Präparat und pharmazeutische Verwendung davon
KR860008282A (ko) 재조합 사람 레닌의 제조방법
JPS5783283A (en) Novel yeast